FDA to review Champix side effects

The US Food and Drugs Administration (FDA) is to review the safety of smoking cessation drug varenicline (Champix) following reports of suicidal, aggressive and erratic behaviour.

Some of these reports have come from the manufacturer of the drug, Pfizer, and others from the media and the internet, the regulator said.

There have also been reports of drowsiness, to the point of affecting the ability to drive, associated with the use of Champix.

A Pfizer UK spokesperson said that there is no scientific evidence establishing a causal relationship between varenicline and the post-marketing report events, and the role of Champix, marketed as Chantix in the US, is still unknown.

The agency has now asked Pfizer for any additional cases of side-effects that it is aware of and is currently reviewing the data.

The FDA recommends that GPs monitor patients taking Champix for behaviour and mood changes.

The Pfizer spokesperson said it was too early to speculate on any potential impact the review would have on the marketing of Champix in the UK but said the pharmaceutical manufacturer was in close contact with the European Medicines Evaluation Agency (EMEA) regarding the FDA communication.

'Pfizer is assessing the potential impact on the European product information and will continue to collaborate with the EMEA on any further developments,' said Pfizer in a statement.

Champix was licensed by the European Medicines Agency (EMA) in September 2006 and was made available on the NHS.

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

First-dose COVID-19 vaccine supply for GP sites to stop completely for a fortnight

First-dose COVID-19 vaccine supply for GP sites to stop completely for a fortnight

Supplies of COVID-19 vaccine for first-dose vaccinations at GP-led vaccination sites...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

More than 70% of COVID-19 jabs this month have been second doses

More than 70% of COVID-19 jabs this month have been second doses

More than seven in 10 COVID-19 jabs administered UK-wide since the start of April...

Accountant's theft of more than £60,000 from GP practices uncovered in pandemic

Accountant's theft of more than £60,000 from GP practices uncovered in pandemic

An accountant has been handed a suspended jail term after stealing more than £60,000...

GMC to contact thousands of GPs due to revalidate from August

GMC to contact thousands of GPs due to revalidate from August

The GMC is writing to thousands of doctors due to revalidate from August to set out...

NHS England spells out next steps as GPs told to cancel AZ jabs booked for under-30s

NHS England spells out next steps as GPs told to cancel AZ jabs booked for under-30s

GP-led vaccination sites should offer under-30s due to receive a first dose of AstraZeneca...